Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 50

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 50
---
-</div>

Overhang The following table provides certain information regarding our equity incentive program as of April 18, 2025:

| Total number of common shares subject to outstanding stock options       |     |            |  33,284,775 |
|:-------------------------------------------------------------------------|:----|:-----------|------------:|
| Weighted-average exercise price of outstanding stock options             |     | $          |        1.60 |
| Weighted-average remaining term of outstanding stock options             |     | 7.44 years |             |
| Total number of common shares subject to outstanding full value awards   |     |            |     334,195 |
| Total number of common shares available for grant under the 2021 Plan(1) |     |            |  15,468,280 |
| Total number of common shares outstanding                                |     |            | 228,356,290 |
| Per-share closing price of common shares as reported on NYSE American    |     | $          |        0.41 |

(1) There were no shares available for grant under any of our other equity incentive plans. We Manage Our Equity Award Use Carefully We continue to believe that equity awards such as stock options and restricted stock units are a vital part of our overall compensation program. Our compensation philosophy reflects broad-based eligibility for equity awards, and we grant equity awards to substantially all of our employees. However, we recognize that equity awards dilute existing shareholders, and, therefore, we must responsibly manage the growth of our equity compensation program. We are committed to effectively monitoring our equity compensation share reserve, including our “burn rate,” in a manner intended to maximize shareholders’ value by granting the appropriate number of equity awards necessary to attract, reward, and retain employees. The Size of Our Share Reserve Request Is Reasonable If this proposal is approved by our shareholders, then subject to adjustment for certain changes in our capitalization, we will have 34,968,280 shares available for grant under the 2021 Plan, plus the Prior Plan Returning Shares (as defined in the 2021 Plan and described below), as such shares become available from time to time. Absent any unforeseen circumstances, we anticipate seeking shareholder approval of an increase in the number of shares available for Awards under the 2021 Plan in 2027. Burn Rate The following table provides detailed information regarding the activity related to our equity incentive program for the fiscal years indicated.

|                                                      |     | Fiscal Year |             |   |     |